Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells

  • Morell, María Cecilia
  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Vara Ciruelos, Diana|||0000-0002-9508-2648
  • Ramos Torres, Ágata
  • Rodríguez Henche, María de las Nieves|||0000-0001-9798-359X
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
BACKGROUND: Neuroendocrine (NE) differentiation represents a common feature of prostate cancer and is associated with accelerated disease progression and poor clinical outcome. Nowadays, there is no treatment for this aggressive form of prostate cancer. The aim of this study was to determine the influence of the cannabinoid WIN 55,212-2 (WIN, a non-selective cannabinoid CB1 and CB2 receptor agonist) on the NE differentiation of prostate cancer cells. METHODS: NE differentiation of prostate cancer LNCaP cells was induced by serum deprivation or by incubation with interleukin-6, for 6 days. Levels of NE markers and signaling proteins were determined by western blotting. Levels of cannabinoid receptors were determined by quantitative PCR. The involvement of signaling cascades was investigated by pharmacological inhibition and small interfering RNA. RESULTS: The differentiated LNCaP cells exhibited neurite outgrowth, and increased the expression of the typical NE markers neuron-specific enolase and ?III tubulin (?III Tub). Treatment with 3??M WIN inhibited NK differentiation of LNCaP cells. The cannabinoid WIN downregulated the PI3K/Akt/mTOR signaling pathway, resulting in NE differentiation inhibition. In addition, an activation of AMP-activated protein kinase (AMPK) was observed in WIN-treated cells, which correlated with a decrease in the NE markers expression. Our results also show that during NE differentiation the expression of cannabinoid receptors CB1 and CB2 dramatically decreases. CONCLUSIONS: Taken together, we demonstrate that PI3K/Akt/AMPK might be an important axis modulating NE differentiation of prostate cancer that is blocked by the cannabinoid WIN, pointing to a therapeutic potential of cannabinoids against NE prostate cancer., Ministerio de Economía y Competitividad, Junta de Comunidades de Castilla-La Mancha, Fundación Tatiana Pérez de Guzmán el Bueno, Fondo Europeo de Desarrollo Regional, Comunidad de Madrid
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation

  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Quesada Sánchez, Sergio
  • Ramos Torres, Ágata
  • Gargantilla López, Marta
  • Priego, Eva Maria
  • Raynal, Sophie
  • Lepifre, Franck
  • Gasalla Herráiz, José Manuel
  • Rodríguez Henche, María de las Nieves|||0000-0001-9798-359X
  • Castro Morera, Ana
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
The key metabolic sensor adenosine monophosphate-dependent kinase (AMPK) has emerged as a promising therapeutic target for cancer prevention and treatment. Besides its role in energy homeostasis, AMPK blocks cell cycle, regulates autophagy and suppresses the anabolic processes required for rapid cell growth. AMPK is especially relevant in prostate cancer in which activation of lipogenic pathways correlate with tumor progression and aggressiveness. This study reports the discovery of a new series of 2-oxindole derivatives whose AMPK modulatory ability, as well as the antitumoral profile in prostate cancer cells, was evaluated. One of the assayed compounds, compound 8c, notably activated AMPK in cultured PC-3, DU145 and LNCaP prostate cancer cells. Likewise, compound 8c caused PC-3, DU145 and LNCaP cells viability inhibition. Selective knocking down of ?1 or ?2 isoforms as well as in vitro assays using human recombinant ?1?1?1 or ?2?1?1 AMPK isoforms revealed that compound 8c exhibit preference for AMPK?1. Consistent with efficacy at the cellular level, compound 8c was potent in suppressing the growth of PC-3 xenograft tumors. In conclusion, our results show that a new 2-oxindole fluorinated derivative exerts potent in vivo antitumor actions against prostate cancer cells, indicating a promising clinical therapeutic strategy for the treatment of androgen-independent prostate cancer., Ministerio de Economía y Competitividad, Junta de Comunidades de Castilla-La Mancha, Fondo Europeo de Desarrollo Regional, Comunidad Autónoma de Madrid, Fundación Tatiana Pérez de Guzmán el Bueno, Junta para la Ampliacion de Estudios
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Capsaicin Targets Lipogenesis in HepG2 Cells Through AMPK Activation, AKT Inhibition and PPARs Regulation

  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Sánchez Gómez, Belén|||0000-0003-0971-1522
  • Mateos Gómez, Pedro Antonio|||0000-0002-5539-2289
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
  • Rodríguez Henche, María de las Nieves|||0000-0001-9798-359X
Obesity, a major risk factor for chronic diseases such as type 2 diabetes (T2D), represents a serious primary health problem worldwide. Dietary habits are of special interest to prevent and counteract the obesity and its associated metabolic disorders, including lipid steatosis. Capsaicin, a pungent compound of chili peppers, has been found to ameliorate diet-induced obesity in rodents and humans. The purpose of this study was to examine the effect of capsaicin on hepatic lipogenesis and to delineate the underlying signaling pathways involved, using HepG2 cells as an experimental model. Cellular neutral lipids, stained with BODIPY493/503, were quantified by flow cytometry, and the protein expression and activity were determined by immunoblotting. Capsaicin reduced basal neutral lipid content in HepG2 cells, as well that induced by troglitazone or by oleic acid. This effect of capsaicin was prevented by dorsomorphin and GW9662, pharmacological inhibitors of AMPK and PPARgamma, respectively. In addition, capsaicin activated AMPK and inhibited the AKT/mTOR pathway, major regulators of hepatic lipogenesis. Furthermore, capsaicin blocked autophagy and increased PGC-1alfa protein. These results suggest that capsaicin behaves as an anti-lipogenic compound in HepG2 cells., Fundación Tatiana Pérez De Guzmán